240 related articles for article (PubMed ID: 26492560)
81. Safety and Efficacy of Fecal Microbiota Transplantation for Grade IV Steroid Refractory GI-GvHD Patients: Interim Results From FMT2017002 Trial.
Zhao Y; Li X; Zhou Y; Gao J; Jiao Y; Zhu B; Wu D; Qi X
Front Immunol; 2021; 12():678476. PubMed ID: 34220825
[TBL] [Abstract][Full Text] [Related]
82. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.
Maury S; Lemoine FM; Hicheri Y; Rosenzwajg M; Badoual C; Cheraï M; Beaumont JL; Azar N; Dhedin N; Sirvent A; Buzyn A; Rubio MT; Vigouroux S; Montagne O; Bories D; Roudot-Thoraval F; Vernant JP; Cordonnier C; Klatzmann D; Cohen JL
Sci Transl Med; 2010 Jul; 2(41):41ra52. PubMed ID: 20650872
[TBL] [Abstract][Full Text] [Related]
83. The initial phase of graft-versus-host disease is associated with a decrease of CD4+CD25+ regulatory T cells in the peripheral blood of patients after allogeneic stem cell transplantation.
Schneider M; Munder M; Karakhanova S; Ho AD; Goerner M
Clin Lab Haematol; 2006 Dec; 28(6):382-90. PubMed ID: 17105491
[TBL] [Abstract][Full Text] [Related]
84. [Role of monoclonal antibodies in the treatment of acute graft versus host disease].
Bay JO; Cabrespine A; Peffault de Latour R
Bull Cancer; 2007 Jan; 94(1):33-41. PubMed ID: 17237003
[TBL] [Abstract][Full Text] [Related]
85. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system.
Luft T; Dietrich S; Falk C; Conzelmann M; Hess M; Benner A; Neumann F; Isermann B; Hegenbart U; Ho AD; Dreger P
Blood; 2011 Aug; 118(6):1685-92. PubMed ID: 21636856
[TBL] [Abstract][Full Text] [Related]
86. Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study.
Liu SN; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ; Mo XD
Am J Hematol; 2020 Aug; 95(8):927-936. PubMed ID: 32311156
[TBL] [Abstract][Full Text] [Related]
87. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Ho VT; Zahrieh D; Hochberg E; Micale E; Levin J; Reynolds C; Steckel S; Cutler C; Fisher DC; Lee SJ; Alyea EP; Ritz J; Soiffer RJ; Antin JH
Blood; 2004 Aug; 104(4):1224-6. PubMed ID: 15113758
[TBL] [Abstract][Full Text] [Related]
88. High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus-host disease in the absence of statin therapy.
Dietrich S; Okun JG; Schmidt K; Falk CS; Wagner AH; Karamustafa S; Radujkovic A; Hegenbart U; Ho AD; Dreger P; Luft T
Haematologica; 2014 Mar; 99(3):541-7. PubMed ID: 24142995
[TBL] [Abstract][Full Text] [Related]
89. Graft versus host disease as a complication after liver transplantation: A rare but serious association.
Pérez-Saborido B; Asensio-Díaz E; Barrera-Rebollo A; Rodríguez-López M; Gonzalo-Martín M; Madrigal-Rubiales B; García-Pajares F; Pacheco-Sánchez D
Rev Esp Enferm Dig; 2016 Jan; 108(1):49-50. PubMed ID: 26765238
[TBL] [Abstract][Full Text] [Related]
90. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis.
Creed TJ; Norman MR; Probert CS; Harvey RF; Shaw IS; Smithson J; Anderson J; Moorghen M; Gupta J; Shepherd NA; Dayan CM; Hearing SD
Aliment Pharmacol Ther; 2003 Jul; 18(1):65-75. PubMed ID: 12848627
[TBL] [Abstract][Full Text] [Related]
91. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab.
Willenbacher W; Basara N; Blau IW; Fauser AA; Kiehl MG
Br J Haematol; 2001 Mar; 112(3):820-3. PubMed ID: 11260089
[TBL] [Abstract][Full Text] [Related]
92. Novel strategies for steroid-refractory acute graft-versus-host disease.
Bolaños-Meade J; Vogelsang GB
Curr Opin Hematol; 2005 Jan; 12(1):40-4. PubMed ID: 15604890
[TBL] [Abstract][Full Text] [Related]
93. Salvage therapy with basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease.
Freyer CW; Gier S; Carulli A; Gill SI; Hexner EO; Loren AW; Martin ME; Porter DL
Am J Hematol; 2022 Jul; 97(7):E273-E276. PubMed ID: 35413140
[No Abstract] [Full Text] [Related]
94. The Potential of Mesenchymal Stromal Cells as Treatment for Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Critical Review of the Literature.
Munneke JM; Spruit MJ; Cornelissen AS; van Hoeven V; Voermans C; Hazenberg MD
Transplantation; 2016 Nov; 100(11):2309-2314. PubMed ID: 26714122
[TBL] [Abstract][Full Text] [Related]
95. Tocilizumab for the treatment of steroid refractory graft-versus-host disease.
Drobyski WR; Pasquini M; Kovatovic K; Palmer J; Douglas Rizzo J; Saad A; Saber W; Hari P
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1862-8. PubMed ID: 21745454
[TBL] [Abstract][Full Text] [Related]
96. Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation.
Pagliuca S; Prata PH; Xhaard A; Frieri C; Giannoni L; Sutra Del Galy A; Brignier A; Sicre de Fontbrune F; Michonneau D; Dhedin N; Peffault de Latour R; Socié G; Robin M
Bone Marrow Transplant; 2021 Jan; 56(1):38-49. PubMed ID: 32587336
[TBL] [Abstract][Full Text] [Related]
97. Bortezomib for the prevention and treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Al-Homsi AS; Feng Y; Duffner U; Al Malki MM; Goodyke A; Cole K; Muilenburg M; Abdel-Mageed A
Exp Hematol; 2016 Sep; 44(9):771-777. PubMed ID: 27224851
[TBL] [Abstract][Full Text] [Related]
98. Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin.
Marcondes AM; Hockenbery D; Lesnikova M; Dinarello CA; Woolfrey A; Gernsheimer T; Loghman-Adham M; Gelmont D; Storer B; Hansen JA; Deeg HJ
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1596-1601. PubMed ID: 27223109
[TBL] [Abstract][Full Text] [Related]
99. New strategies in the treatment of graft-versus-host disease.
Basara N; Blau IW; Willenbacher W; Kiehl MG; Fauser AA
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S12-5. PubMed ID: 10933179
[TBL] [Abstract][Full Text] [Related]
100. Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease.
Dartois C; Freyer G; Michallet M; Hénin E; You B; Darlavoix I; Vermot-Desroches C; Tranchand B; Girard P
Clin Pharmacokinet; 2007; 46(5):417-32. PubMed ID: 17465640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
